Long-term use of an ultrapotent topical steroid for the treatment of vulval lichen sclerosus is safe.
a St John's Institute of Dermatology, Guy's Hospital, Great Maze Pond , London , United Kingdom.
A
A
Kai
a St John's Institute of Dermatology, Guy's Hospital, Great Maze Pond , London , United Kingdom.
F
F
Lewis
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002181:Candidiasis, Vulvovaginal / Q000139:chemically induced; D002990:Clobetasol / Q000008:administration & dosage* / Q000009:adverse effects; D004060:Diflucortolone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006558:Herpes Genitalis / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000139:chemically induced; D013684:Telangiectasis / Q000139:chemically induced; D013997:Time Factors; D007724:Vulvar Lichen Sclerosus / Q000188:drug therapy*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; C013486:diflucortolone valerate; D002990:Clobetasol; D004060:Diflucortolone